Inhibitory effects of dimethylacetyl-β-cyclodextrin on lipopolysaccharide-induced macrophage activation and endotoxin shock in mice

Biochemical Pharmacology

Volumn 70, Issue 10, 2005, Pages 1506-1517

  Arima, Hidetoshi ^a   Motoyama, Keiichi ^a   Matsukawa, Akihiro ^b   Nishimoto, Yoji ^a   Hirayama, Fumitoshi ^a   Uekama, Kaneto ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Antagonist; Cyclodextrin; Dimethylacetyl cyclodextrin; Lipopolysaccharide; Macrophages; Sepsis

Indexed keywords

2,6 DI O METHYL 3 O ACETYL BETA CYCLODEXTRIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA CYCLODEXTRIN DERIVATIVE; GALACTOSAMINE; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; NITRIC OXIDE; OLIGONUCLEOTIDE; PEPTIDOGLYCAN; POLYINOSINIC POLYCYTIDYLIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK;

ANIMALS; ASPARTATE AMINOTRANSFERASES; BETA-CYCLODEXTRINS; CELL LINE; CELL NUCLEUS; CELL SURVIVAL; CYCLODEXTRINS; DRUG INTERACTIONS; GALACTOSAMINE; LIGANDS; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGE INFLAMMATORY PROTEINS; MICE; NF-KAPPA B; NITRIC OXIDE; SHOCK, SEPTIC; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 26944480084     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.08.021     Document Type: Article

References (40)

1. J.C. Marshall Such stuff as dreams are made on: mediator-directed therapy in sepsis Nat Rev Drug Discov 2 2003 391 405
2. N.C. Riedemann, R.F. Guo, and P.A. Ward Novel strategies for the treatment of sepsis Nat Med 9 2003 517 524
3. P. Katsikis, G. Harris, T. Page, E. Paleolog, M. Feldman, and M.R. Dalesandro Antilipid a monoclonal antibody HA-1A: immune complex clearance of endotoxin reduces TNF-α, IL-1 β and IL-6 production Cytokine 5 1993 348 353
4. M. Lynn, D.P. Rossignol, J.L. Wheeler, R.J. Kao, C.A. Perdomo, and R. Noveck Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia J Infect Dis 187 2003 631 639
5. M.A. Seelen, P. Athanassiou, W.A. Lynn, P. Norsworthy, M.J. Walport, and J. Cohen The anti-lipid A monoclonal antibody E5 binds to rough Gram-negative bacteria, fixes C3, and facilitates binding of bacterial immune complexes to both erythrocytes and monocytes Immunology 84 1995 653 661
6. D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M.R. Pinsky Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care Crit Care Med 29 2001 1303 1310
7. D.C. Angus, M.C. Birmingham, R.A. Balk, P.J. Scannon, D. Collins, and J.A. Kruse E5 murine monoclonal antiendotoxin antibody in Gram-negative sepsis: a randomized controlled trial. E5 Study Investigators JAMA 283 2000 1723 1730
8. D.L. Dunn Prevention and treatment of multiple organ dysfunction syndrome: lessons learned and future prospects Surg Infect 1 2000 227 237
9. C.T. Esmon Why do animal models (sometimes) fail to mimic human sepsis? Crit Care Med 32 5 Suppl. 2004 S219 S222
10. M.E. Davis, and M.E. Brewster Cyclodextrin-based pharmaceutics: past, present and future Nat Rev Drug Discov 3 2004 1023 1035
11. K. Uekama, F. Hirayama, and T. Irie Cyclodextrin drug carrier systems Chem Rev 98 1998 2045 2076
12. T. Irie, M. Otagiri, M. Sunada, K. Uekama, Y. Ohtani, and Y. Yamada Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro J Pharmacobiodyn 5 1982 741 744
13. T. Irie, and K. Uekama Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation J Pharm Sci 86 1997 147 162
14. Y. Ohtani, T. Irie, K. Uekama, K. Fukunaga, and J. Pitha Differential effects of α-, β- and γ-cyclodextrins on human erythrocytes Eur J Biochem 186 1989 17 22
15. F. Galbiati, B. Razani, and M.P. Lisanti Emerging themes in lipid rafts and caveolae Cell 106 2001 403 411
16. K. Simons, and R. Ehehalt Cholesterol, lipid rafts, and disease J Clin Invest 110 2002 597 603
17. F. Van Laethem, and O. Leo Membrane lipid rafts: new targets for immunoregulation Curr Mol Med 2 2002 557 570
18. H. Arima, K. Yunomae, F. Hirayama, and K. Uekama Contribution of P-glycoprotein to the enhancing effects of dimethyl-β-cyclodextrin on oral bioavailability of tacrolimus J Pharmacol Exp Ther 297 2001 547 555
19. H. Arima, Y. Nishimoto, K. Motoyama, F. Hirayama, and K. Uekama Inhibitory effects of novel hydrophilic cyclodextrin derivatives on nitric oxide production in macrophages stimulated with lipopolysaccharide Pharm Res 18 2001 1167 1173
20. K. Motoyama, H. Arima, Y. Nishimoto, K. Miyake, F. Hirayama, and K. Uekama Involvement of CD14 in the inhibitory effects of dimethyl-α- cyclodextrin on lipopolysaccharide signaling in macrophages FEBS Lett 579 2005 1707 1714
21. F. Hirayama, S. Mieda, Y. Miyamoto, H. Arima, and K. Uekama Heptakis(2,6-di-O-methyl-3-O-acetyl)-β-cyclodextrin: a water-soluble cyclodextrin derivative with low hemolytic activity J Pharm Sci 88 1999 970 975
22. K. Hamasaki, K. Kogure, and K. Ohwada A biological method for the quantitative measurement of tetrodotoxin (TTX): tissue culture bioassay in combination with a water-soluble tetrazolium salt Toxicon 34 1996 490 495
23. N. Ono, H. Arima, F. Hirayama, and K. Uekama A moderate interaction of maltosyl-alpha-cyclodextrin with Caco-2 cells in comparison with the parent cyclodextrin Biol Pharm Bull 24 2001 395 402
24. D.J. Stuehr, and C.F. Nathan Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells J Exp Med 169 1989 1543 1555
25. M.P. Lisanti, Z. Tang, P.E. Scherer, and M. Sargiacomo Caveolae purification and glycosylphosphatidylinositol-linked protein sorting in polarized epithelia Methods Enzymol 250 1995 655 668
26. A. Matsukawa, K. Takeda, S. Kudo, T. Maeda, M. Kagayama, and S. Akira Aberrant inflammation and lethality to septic peritonitis in mice lacking STAT3 in macrophages and neutrophils J Immunol 171 2003 6198 6205
27. M.D. Digan, H. Ataoglu, and E.S. Akarsu Effects of different serotypes of Escherichia coli lipopolysaccharides on body temperature in rats Life Sci 67 2000 2319 2329
28. A.F. Quest, L. Leyton, and M. Parraga Caveolins, caveolae, and lipid rafts in cellular transport, signaling, and disease Biochem Cell Biol 82 2004 129 144
29. A. Pfeiffer, A. Bottcher, E. Orso, M. Kapinsky, P. Nagy, and A. Bodnar Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts Eur J Immunol 31 2001 3153 3164
30. L. Szente, and J. Szejtli Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development Adv Drug Deliv Rev 36 1999 17 28
31. E.M. Pålsson-Mcdermott, and L.A.J. O'Neill Signal transduction by the lipopolysaccharide receptor. Toll-like receptor-4 Immunology 113 2004 153 162
32. E.P. Kilsdonk, P.G. Yancey, G.W. Stoudt, F.W. Bangerter, W.J. Johnson, and M.C. Phillips Cellular cholesterol efflux mediated by cyclodextrins J Biol Chem 270 1995 17250 17256
33. K. Simons, and D. Toomre Lipid rafts and signal transduction Nat Rev Mol Cell Biol 1 2000 31 39
34. D.N. Fish Optimal antimicrobial therapy for sepsis Am J Health Syst Pharm 59 Suppl. 1 2002 S13 S19
35. O.H. Hultgren, L. Svensson, and A. Tarkowski Critical role of signaling through IL-1 receptor for development of arthritis and sepsis during Staphylococcus aureus infection J Immunol 168 2002 5207 5212
36. J.E. Wang, M.K. Dahle, M. McDonald, S.J. Foster, A.O. Aasen, and C. Thiemermann Peptidoglycan and lipoteichoic acid in Gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism Shock 20 2003 402 414
37. M. Mullarkey, J.R. Rose, J. Bristol, T. Kawata, A. Kimura, and S. Kobayashi Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist J Pharmacol Exp Ther 304 3 2003 1093 1102
38. Y. Fujihara, W.C. Bogard, M.G. Lei, P.E. Daddona, and D.C. Morrison Monoclonal anti-lipid A IgM antibodies HA-1A and E-5 recognize distinct epitopes on lipopolysaccharide and lipid A J Infect Dis 168 1993 1429 1435
39. M. Fujihara, M. Muroi, K. Tanamoto, T. Suzuki, H. Azuma, and H. Ikeda Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex Pharmacol Ther 100 2003 171 194
40. J.F. Alcorn, and J.R. Wright Surfactant protein A inhibits alveolar macrophage cytokine production by CD14-independent pathway Am J Physiol Lung Cell Mol Physiol 286 2004 L129 L136